MCID: PSD007
MIFTS: 54

Pseudomyxoma Peritonei

Categories: Rare diseases, Cancer diseases

Aliases & Classifications for Pseudomyxoma Peritonei

MalaCards integrated aliases for Pseudomyxoma Peritonei:

Name: Pseudomyxoma Peritonei 12 72 49 55 51 41 14 69
Pmp 49 55
Syndrome of Pseudomyxoma Peritonei 49
Gelatinous Ascites 55
Mucinous Ascites 12
Adenomucinosis 55

Characteristics:

Orphanet epidemiological data:

55
pseudomyxoma peritonei
Prevalence: 1-9/1000000 (Worldwide); Age of onset: Adult; Age of death: any age;

Classifications:



External Ids:

Disease Ontology 12 DOID:3559
MeSH 41 D011553
NCIt 46 C3345
SNOMED-CT 64 112679004 307601000
Orphanet 55 ORPHA26790
MESH via Orphanet 42 D011553
UMLS via Orphanet 70 C0033822
ICD10 via Orphanet 33 C78.6
UMLS 69 C0033822

Summaries for Pseudomyxoma Peritonei

NIH Rare Diseases : 49 Pseudomyxoma peritonei (PMP) is a rare disease characterized by the presence of mucin in the abdominal (peritoneal) cavity. While the most common cause of PMP is appendix cancer, several types of tumors (including non-cancerous tumors) can cause PMP. Signs and symptoms may include an increase in abdominal size or bloating; inguinal hernia (in men); an ovarian mass that may be felt during a routine pelvic exam (in women); pain or discomfort in the abdomen; and/or appendicitis. Treatment depends on the underlying cause of the condition (the location and type of the original tumor, including whether it is malignant) and the extent of spreading. A combination of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy is often the most successful treatment. Last updated: 1/31/2018

MalaCards based summary : Pseudomyxoma Peritonei, also known as pmp, is related to microinvasive gastric cancer and intestinal obstruction, and has symptoms including ascites, weight loss and nausea and vomiting. An important gene associated with Pseudomyxoma Peritonei is MUC2 (Mucin 2, Oligomeric Mucus/Gel-Forming), and among its related pathways/superpathways are Gastric cancer and Development EGFR signaling pathway. The drugs Cisplatin and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include appendix, colon and small intestine, and related phenotype is digestive/alimentary.

Disease Ontology : 12 An appendix cancer that is characterized by progressive accumulation of mucus-secreting tumor cells within the abdomen and pelvis.

Wikipedia : 72 Pseudomyxoma peritonei (PMP) is a clinical condition caused by cancerous cells (mucinous adenocarcinoma)... more...

Related Diseases for Pseudomyxoma Peritonei

Diseases related to Pseudomyxoma Peritonei via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 270)
# Related Disease Score Top Affiliating Genes
1 microinvasive gastric cancer 30.5 CDX2 MUC2
2 intestinal obstruction 30.4 CDX2 KRT20 KRT7
3 mucinous cystadenocarcinoma 30.4 KRT20 KRT7 MUC1 MUC2
4 mucinous adenocarcinoma 30.4 CDX2 KRAS KRT20 KRT7 MUC1 MUC2
5 teratoma 30.1 CDX2 KRT20 KRT7 TP53
6 cystadenocarcinoma 30.0 KRT7 MUC1 MUC2 TP53
7 mature teratoma 29.9 KRAS TP53
8 adenocarcinoma 29.9 KRAS MUC1 TP53
9 adenomyoma 29.8 KRT7 MUC1 MUC6
10 cystadenoma 29.7 KRT20 KRT7 MUC1 MUC2 MUC6
11 lynch syndrome 29.6 KRAS MUC2 TP53
12 villous adenoma 29.5 CDX2 KRAS KRT20 MUC1
13 colloid carcinoma of the pancreas 29.4 KRAS MUC1 MUC2 MUC5AC
14 appendix cancer 29.4 CDX2 KRAS KRT20 KRT7 MUC1 MUC2
15 cystic teratoma 29.1 CDX2 KRT20 KRT7 MUC2 MUC6 TP53
16 adenoma 29.1 KRAS KRT7 MUC2 MUC5AC TP53
17 ovarian cancer 28.6 KRAS KRT7 MUC1 MUC2 TP53
18 gastric cancer 27.1 CDX2 KRAS KRT20 MUC1 MUC2 MUC5AC
19 colorectal cancer 26.7 CDX2 KRAS KRT20 KRT7 MUC1 MUC2
20 gelatinous ascites 11.5
21 handl syndrome 10.9
22 peritonitis 10.7
23 cystic basal cell carcinoma 10.5 KRT20 KRT7
24 lung acinar adenocarcinoma 10.5 KRT20 KRT7
25 seminal vesicle adenocarcinoma 10.5 KRT20 KRT7
26 transverse colon cancer 10.5 KRT20 KRT7
27 ovarian large-cell neuroendocrine carcinoma 10.5 KRT20 KRT7
28 eyelid neoplasm 10.5 KRT20 KRT7
29 malignant syringoma 10.5 KRT20 KRT7
30 krukenberg carcinoma 10.5 KRT20 KRT7
31 large intestine adenocarcinoma 10.5 KRT20 KRT7
32 linitis plastica 10.5 KRT20 KRT7
33 small cell carcinoma of the bladder 10.5 KRT20 KRT7
34 adenoid squamous cell carcinoma 10.5 KRT20 KRT7
35 mucinous adenofibroma 10.5 CDX2 KRT7
36 vulval paget's disease 10.5 KRT20 KRT7
37 intratubular embryonal carcinoma 10.4 KRT20 KRT7
38 chronic cholangitis 10.4 CDX2 MUC2
39 meibomian cyst 10.4 KRT20 KRT7
40 bladder lymphoma 10.4 KRT20 KRT7
41 epithelial predominant wilms' tumor 10.4 CDX2 KRT7
42 renal pelvis carcinoma 10.4 KRT20 KRT7
43 medulloepithelioma 10.4 KRT20 KRT7
44 cap polyposis 10.4 MUC2 MUC5AC
45 anal gland adenocarcinoma 10.4 KRT7 MUC5AC
46 anus adenocarcinoma 10.4 KRT7 MUC5AC
47 infiltrative basal cell carcinoma 10.4 KRT20 KRT7
48 immune system organ benign neoplasm 10.4 KRT20 KRT7
49 thymus lipoma 10.4 KRT20 KRT7
50 clear cell adenoma 10.4 MUC2 MUC5AC

Graphical network of the top 20 diseases related to Pseudomyxoma Peritonei:



Diseases related to Pseudomyxoma Peritonei

Symptoms & Phenotypes for Pseudomyxoma Peritonei

Human phenotypes related to Pseudomyxoma Peritonei:

55 31 (show all 12)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 ascites 55 31 hallmark (90%) Very frequent (99-80%) HP:0001541
2 weight loss 55 31 occasional (7.5%) Occasional (29-5%) HP:0001824
3 nausea and vomiting 55 31 occasional (7.5%) Occasional (29-5%) HP:0002017
4 constipation 55 31 occasional (7.5%) Occasional (29-5%) HP:0002019
5 abdominal pain 55 31 occasional (7.5%) Occasional (29-5%) HP:0002027
6 inflammation of the large intestine 55 31 frequent (33%) Frequent (79-30%) HP:0002037
7 respiratory insufficiency 55 31 occasional (7.5%) Occasional (29-5%) HP:0002093
8 abnormality of the peritoneum 55 31 hallmark (90%) Very frequent (99-80%) HP:0002585
9 lymphadenopathy 55 31 occasional (7.5%) Occasional (29-5%) HP:0002716
10 abnormality of the abdominal wall 55 31 hallmark (90%) Very frequent (99-80%) HP:0004298
11 intestinal obstruction 55 31 occasional (7.5%) Occasional (29-5%) HP:0005214
12 hernia 55 31 occasional (7.5%) Occasional (29-5%) HP:0100790

MGI Mouse Phenotypes related to Pseudomyxoma Peritonei:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 9.1 CA2 CDX2 KRAS MUC2 MUC5AC TP53

Drugs & Therapeutics for Pseudomyxoma Peritonei

Drugs for Pseudomyxoma Peritonei (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 54)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
2
Fluorouracil Approved Phase 2 51-21-8 3385
3
Oxaliplatin Approved, Investigational Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
4
Amoxicillin Approved, Vet_approved Phase 2 26787-78-0 33613 2171
5
Clarithromycin Approved Phase 2 81103-11-9 84029
6
Dexlansoprazole Approved, Investigational Phase 2 138530-94-6, 103577-45-3 9578005
7
Lansoprazole Approved, Investigational Phase 2 103577-45-3 3883
8
nivolumab Approved Phase 2 946414-94-4
9
leucovorin Approved, Nutraceutical Phase 2,Phase 1 58-05-9 143 6006
10 Anti-Infective Agents Phase 2,Phase 1
11 Antimetabolites Phase 2,Phase 1
12 Antimetabolites, Antineoplastic Phase 2,Phase 1
13 Immunosuppressive Agents Phase 2,Phase 1
14 Antacids Phase 2
15 Anti-Bacterial Agents Phase 2
16 Antibiotics, Antitubercular Phase 2
17 Antitubercular Agents Phase 2
18 Anti-Ulcer Agents Phase 2
19 Cytochrome P-450 CYP3A Inhibitors Phase 2
20 Cytochrome P-450 Enzyme Inhibitors Phase 2
21 Gastrointestinal Agents Phase 2
22 Proton pump inhibitors Phase 2
23 Antibodies Phase 2
24 Antibodies, Monoclonal Phase 2
25 Immunoglobulins Phase 2
26 Mitomycins Phase 2
27 Alkylating Agents Phase 2
28 Nucleic Acid Synthesis Inhibitors Phase 2
29
Carboplatin Approved Phase 1 41575-94-4 10339178 38904 498142
30
Gemcitabine Approved Phase 1 95058-81-4 60750
31
Floxuridine Approved Phase 1 50-91-9 5790
32
Levoleucovorin Approved, Investigational Phase 1 68538-85-2
33 Pancreatic Polypeptide Investigational Phase 1 59763-91-6
34 Antiviral Agents Phase 1
35 Antidotes Phase 1
36 Calcium, Dietary Phase 1
37 Liver Extracts Phase 1
38 Protective Agents Phase 1
39 Cola Nutraceutical Phase 1
40
Doxorubicin Approved, Investigational 23214-92-8 31703
41
Ifosfamide Approved 3778-73-2 3690
42
Thrombin Approved, Investigational
43
Paclitaxel Approved, Vet_approved 33069-62-4 36314
44
Folic Acid Approved, Nutraceutical, Vet_approved 59-30-3 6037
45
Doxil Approved June 1999 31703
46 Coagulants
47 Hemostatics
48 Isophosphamide mustard 0
49 Albumin-Bound Paclitaxel
50 Antimitotic Agents

Interventional clinical trials:

(show all 18)

# Name Status NCT ID Phase Drugs
1 HIPEC Using High Intra-abdominal Pressure Completed NCT02949791 Phase 2
2 Antibiotic Treatment and Long-term Outcomes of Patients With Pseudomyxoma Peritonei of Appendiceal Origin Recruiting NCT02387203 Phase 2 PrevPac (Prevacid, Amoxicillin, Clarithromycin)
3 Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Recruiting NCT02834013 Phase 2
4 Single Arm Study Treating Patients of Peritoneal Surface Malignancy (Colorectal, Appendical, Pseudomyxoma, Gastric) With Cytoreductive Surgery and Hyperthermic Intraperitoneal Mitomycin-C Enrolling by invitation NCT02040142 Phase 2
5 A Phase II Study of Surgical Debulking With Peritonectomy and Biweekly Intraperitoneal 5FU With Systemic Oxaliplatin/5FU/Leucovorin in Patients With Pseudomyxoma Peritonei or Peritoneal Carcinomatosis Terminated NCT00352755 Phase 2 Intraperitoneal 5FU;FOLFOX
6 Carboplatin, Gemcitabine Hydrochloride, and Stereotactic Body Radiation Therapy in Gynecological Cancer Completed NCT01652794 Phase 1 carboplatin;gemcitabine hydrochloride
7 Oxaliplatin With Or Without Floxuridine and Leucovorin in Treating Patients With Metastatic Cancer of the Peritoneum Completed NCT00005860 Phase 1 floxuridine;leucovorin calcium;oxaliplatin
8 Results of CRS and Debulking in PMP Patients Unknown status NCT01427101
9 Thrombin Generation and Platelet Activation in CRS/HIPEC Completed NCT03034850
10 Knowledge, Attitudes, and Practice of Surgeons Toward Nutrition Support in HIPEC Patients Completed NCT02374411
11 Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer Completed NCT01764789
12 Quality of Life and Survivorship Care in Patients Undergoing Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Completed NCT01126346
13 Crossover Trial of Systemic Chemotherapy in Patients With Metastatic Well-Differentiated Mucinous Appendiceal Adenocarcinomas With Pseudomyxoma Peritonei Recruiting NCT01946854
14 Register With Patients in Which Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) Was Performed Recruiting NCT01617382
15 Gastrointestinal Microbiome Study of Appendiceal Cancer Recruiting NCT02599116
16 Peritoneal Surface Malignancies - Characterization, Models and Treatment Strategies Recruiting NCT02073500
17 International Registry of Patients Treated With Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) Recruiting NCT03210298
18 French National Registry of Rare Peritoneal Surface Malignancies Active, not recruiting NCT02834169

Search NIH Clinical Center for Pseudomyxoma Peritonei

Cochrane evidence based reviews: pseudomyxoma peritonei

Genetic Tests for Pseudomyxoma Peritonei

Anatomical Context for Pseudomyxoma Peritonei

MalaCards organs/tissues related to Pseudomyxoma Peritonei:

38
Appendix, Colon, Small Intestine, Ovary, Liver, Pancreas, Testes

Publications for Pseudomyxoma Peritonei

Articles related to Pseudomyxoma Peritonei:

(show top 50) (show all 597)
# Title Authors Year
1
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin. ( 29412465 )
2018
2
Validation of the Recent PSOGI Pathological Classification of Pseudomyxoma Peritonei in a Single-Center Series of 265 Patients Treated by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy. ( 29159742 )
2018
3
Low-dose Pressurized Intrathoracic Aerosol Chemotherapy (PITAC) as an Alternative Therapy for Pleuropulmonary Involvement in Pseudomyxoma Peritonei. ( 29374723 )
2018
4
Prediction of Resectability in Pseudomyxoma Peritonei with a New CT Score. ( 29192372 )
2018
5
Mucinous Neoplasm of the Appendix and Pseudomyxoma Peritonei. ( 29406206 )
2018
6
Pseudomyxoma Peritonei Arising From Urachal Mucinous Adenocarcinoma. ( 29024737 )
2018
7
Long-term Quality of Life After Cytoreductive Surgery and Heated Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei: A Prospective Longitudinal Study. ( 29313146 )
2018
8
Impact of Cellularity on Oncologic Outcomes Following Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemoperfusion for Pseudomyxoma Peritonei. ( 29110275 )
2018
9
A Patient With a Low-grade Mucinous Neoplasm Involving the Ovary and Pseudomyxoma Peritonei Originating in an Isolated Intestinal Duplication. ( 28700427 )
2017
10
Outcomes of cytoreductive surgery and HIPEC for pseudomyxoma peritonei of appendiceal origin from two Indian centers: A preliminary five-year experience. ( 28365962 )
2017
11
Appendix-derived Pseudomyxoma Peritonei (PMP): Molecular Profiling Toward Treatment of a Rare Malignancy. ( 28263231 )
2017
12
Carbonic anhydrase II: a novel biomarker for pseudomyxoma peritonei. ( 28233447 )
2017
13
Liver scalloping in pseudomyxoma peritonei. ( 28255672 )
2017
14
Pseudomyxoma Peritonei as a First Manifestation of KRAS-Mutated Urachal Mucinous Cystadenocarcinoma of the Bladder: A Case Report. ( 28449606 )
2017
15
Computed Tomography Follow-Up Assessment of Patients with Low-Grade Appendiceal Mucinous Neoplasms: Evaluation of Risk for Pseudomyxoma Peritonei. ( 28474197 )
2017
16
Haemodynamic changes during hyperthermic intra-thoracic chemotherapy for pseudomyxoma peritonei. ( 28540781 )
2017
17
Repeat extraperitoneal cesarean section on a woman with pseudomyxoma peritonei. ( 28388871 )
2017
18
Early Postoperative Intraperitoneal Chemotherapy for Low-Grade Appendiceal Mucinous Neoplasms with Pseudomyxoma Peritonei: Is it Beneficial? ( 27718032 )
2017
19
HIV patient with pseudomyxoma peritonei of extra-appendiceal origin is disease-free and alive 9 years after complete cytoreductive surgery. ( 28975983 )
2017
20
Pseudomyxoma peritonei: natural history and treatment. ( 28540829 )
2017
21
Targeting G-protein coupled receptor-related signaling pathway in a murine xenograft model of appendiceal pseudomyxoma peritonei. ( 29290997 )
2017
22
Anaesthetic management of patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei: a retrospective audit. ( 28673220 )
2017
23
Prediction of clinical outcome using blood flow volume in the superior mesenteric artery in patients with pseudomyxoma peritonei treated by cytoreductive surgery. ( 28587731 )
2017
24
Multiple components of PKA and TGF-I^ pathways are mutated in pseudomyxoma peritonei. ( 28426742 )
2017
25
Synchronous Ovarian and Appendiceal Mucinous Neoplasms in the Absence of Pseudomyxoma Peritonei. ( 27870702 )
2017
26
Urachal mucinous adenocarcinoma with pseudomyxoma peritonei: A case report. ( 28858081 )
2017
27
The modified Glasgow prognosis score predicts for overall and disease-free survival following cytoreductive surgery and HIPEC in patients with pseudomyxoma peritonei of appendiceal origin. ( 27866811 )
2017
28
The histopathological classification, diagnosis and differential diagnosis of mucinous appendiceal neoplasms, appendiceal adenocarcinomas and pseudomyxoma peritonei. ( 28746986 )
2017
29
Physical and chemical characteristics of mucin secreted by pseudomyxoma peritonei (PMP). ( 28138305 )
2017
30
Palliative Radiation Therapy for Symptom Control in an Advanced Case of Pseudomyxoma Peritonei. ( 28852603 )
2017
31
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei and appendix tumours in elderly patients: Is it justified? ( 28812240 )
2017
32
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of pseudomyxoma peritonei: A single-center experience. ( 29185227 )
2017
33
An unusual case of pseudomyxoma peritonei associated with synchronous primary mucinous tumors of the ovary and appendix: A case report. ( 28599482 )
2017
34
Pseudomyxoma Peritonei: A Case Report Diagnosed in a 47-Year-Old Woman with Chronic Pelvic Abdominal Pain and Appendicular Origin: Review of the Literature and Management. ( 29326943 )
2017
35
Diagnosis of Pseudomyxoma peritonei via endoscopic ultrasound guided fine needle aspiration: a case report and review of literature. ( 28155576 )
2017
36
Pseudomyxoma peritonei with intrathoracic extension: a rare disease with rarer presentation from low-grade mucinous adenocarcinoma of the appendix. ( 26729823 )
2016
37
Pseudomyxoma peritonei of a mature ovarian teratoma caused by mismatch repair deficiency in a patient with Lynch syndrome: a case report. ( 27938333 )
2016
38
Appendicular mucinous adenocarcinoma associated with pseudomyxoma peritonei, a rare and difficult imaging diagnosis. ( 27239665 )
2016
39
Expression of CEA, CA19-9, CA125, and EpCAM in pseudomyxoma peritonei. ( 27038681 )
2016
40
Pathology of Mucinous Appendiceal Tumors and Pseudomyxoma Peritonei. ( 27065718 )
2016
41
Advanced Pseudomyxoma Peritonei Requiring Gastrectomy to Achieve Complete Cytoreduction Results in Good Long-Term Oncologic Outcomes. ( 27380645 )
2016
42
Incidentally discovered low-grade appendiceal mucinous neoplasm: a precursor to pseudomyxoma peritonei. ( 27980743 )
2016
43
A rare, low-grade appendiceal mucinous neoplasm (Pseudomyxoma peritonei) with ossification: A case report with morphoproteomic analysis of bone formation. ( 27712976 )
2016
44
Patient-derived xenograft mouse models of pseudomyxoma peritonei recapitulate the human inflammatory tumor microenvironment. ( 26833741 )
2016
45
Incidence of leukopenia after intraperitoneal vs combined intravenous/intraperitoneal chemotherapy in pseudomyxoma peritonei. ( 27602245 )
2016
46
Should total gastrectomy and total colectomy be considered for selected patients with severe tumor burden of pseudomyxoma peritonei in cytoreductive surgery? ( 27241925 )
2016
47
Pseudomyxoma Peritonei in a Patient with History of Breast Cancer. ( 26996187 )
2016
48
Pseudomyxoma Peritonei: Symptom Control and Objective Radiological Response after Treatment with Lanreotide Autogel. ( 26933420 )
2016
49
FDG-PET/ceCT is useful to predict recurrence of Pseudomyxoma peritonei. ( 26907364 )
2016
50
Mucinous Balls Tangled With Mesothelial Cells and MUC2-Positive Cancer Cells in the Ascites of Pseudomyxoma Peritonei. ( 27079739 )
2016

Variations for Pseudomyxoma Peritonei

Cosmic variations for Pseudomyxoma Peritonei:

9 (show top 50) (show all 75)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM1035874 VHL peritoneum,appendix,other,pseudomyxoma peritonei c.430G>A p.G144R 8
2 COSM10648 TP53 peritoneum,appendix,other,pseudomyxoma peritonei c.524G>A p.R175H 8
3 COSM11205 TP53 peritoneum,appendix,other,pseudomyxoma peritonei c.796G>C p.G266R 8
4 COSM10771 TP53 peritoneum,appendix,other,pseudomyxoma peritonei c.749C>T p.P250L 8
5 COSM10659 TP53 peritoneum,appendix,other,pseudomyxoma peritonei c.817C>T p.R273C 8
6 COSM10777 TP53 peritoneum,appendix,other,pseudomyxoma peritonei c.715A>G p.N239D 8
7 COSM1150895 SMAD4 peritoneum,appendix,other,pseudomyxoma peritonei c.1157G>A p.G386D 8
8 COSM14122 SMAD4 peritoneum,appendix,other,pseudomyxoma peritonei c.1082G>A p.R361H 8
9 COSM1150828 SMAD4 peritoneum,appendix,other,pseudomyxoma peritonei c.1495T>C p.C499R 8
10 COSM4169157 SMAD2 peritoneum,appendix,other,pseudomyxoma peritonei c.1391C>T p.S464L 8
11 COSM4169135 SMAD2 peritoneum,appendix,other,pseudomyxoma peritonei c.1388G>A p.C463Y 8
12 COSM4169134 SMAD2 peritoneum,appendix,other,pseudomyxoma peritonei c.1400C>T p.S467L 8
13 COSM1570338 RET peritoneum,appendix,other,pseudomyxoma peritonei c.2651A>T p.E884V 8
14 COSM763 PIK3CA peritoneum,appendix,other,pseudomyxoma peritonei c.1633G>A p.E545K 8
15 COSM12591 PIK3CA peritoneum,appendix,other,pseudomyxoma peritonei c.3127A>G p.M1043V 8
16 COSM4755600 PDGFRA peritoneum,appendix,other,pseudomyxoma peritonei c.1658C>T p.P553L 8
17 COSM580 NRAS peritoneum,appendix,other,pseudomyxoma peritonei c.181C>A p.Q61K 8
18 COSM521 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.35G>A p.G12D 8
19 COSM520 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.35G>T p.G12V 8
20 COSM4169153 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.389C>T p.A130V 8
21 COSM532 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.38G>A p.G13D 8
22 COSM4169137 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.418C>T p.P140S 8
23 COSM1562184 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.25G>A p.V9I 8
24 COSM516 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.34G>T p.G12C 8
25 COSM522 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.35G>C p.G12A 8
26 COSM1169214 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.101C>T p.P34L 8
27 COSM4169147 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.412G>A p.G138R 8
28 COSM539 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.44G>A p.G15D 8
29 COSM110699 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.29G>A p.G10E 8
30 COSM3727814 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.91G>A p.E31K 8
31 COSM4169161 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.59C>T p.T20M 8
32 COSM51382 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.50G>A p.S17N 8
33 COSM4169149 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.380C>T p.T127I 8
34 COSM12722 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.40G>A p.V14I 8
35 COSM527 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.37G>T p.G13C 8
36 COSM517 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.34G>A p.G12S 8
37 COSM1360888 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.28G>A p.G10R 8
38 COSM529 KRAS peritoneum,appendix,other,pseudomyxoma peritonei c.37G>C p.G13R 8
39 COSM27895 GNAS peritoneum,appendix,other,pseudomyxoma peritonei c.602G>A p.R201H 8
40 COSM1685346 GNAS peritoneum,appendix,other,pseudomyxoma peritonei c.677G>A p.G226D 8
41 COSM27887 GNAS peritoneum,appendix,other,pseudomyxoma peritonei c.601C>T p.R201C 8
42 COSM99221 GNAS peritoneum,appendix,other,pseudomyxoma peritonei c.602G>T p.R201L 8
43 COSM4169159 GNAS peritoneum,appendix,other,pseudomyxoma peritonei c.596G>A p.R199H 8
44 COSM4169145 GNAS peritoneum,appendix,other,pseudomyxoma peritonei c.643G>A p.D215N 8
45 COSM302311 GNAS peritoneum,appendix,other,pseudomyxoma peritonei c.692G>A p.R231H 8
46 COSM4169155 GNAS peritoneum,appendix,other,pseudomyxoma peritonei c.706C>T p.Q236* 8
47 COSM4386691 ATM peritoneum,appendix,other,pseudomyxoma peritonei c.3980T>G p.L1327* 8
48 COSM33765 AKT1 peritoneum,appendix,other,pseudomyxoma peritonei c.49G>A p.E17K 8
49 COSM123397 peritoneum,appendix,other,pseudomyxoma peritonei c.2530C>T p.R844C 8
50 COSM1152506 peritoneum,appendix,other,pseudomyxoma peritonei c.34G>A p.G12S 8

Expression for Pseudomyxoma Peritonei

Search GEO for disease gene expression data for Pseudomyxoma Peritonei.

Pathways for Pseudomyxoma Peritonei

GO Terms for Pseudomyxoma Peritonei

Cellular components related to Pseudomyxoma Peritonei according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 Golgi lumen GO:0005796 8.92 MUC1 MUC2 MUC5AC MUC6

Biological processes related to Pseudomyxoma Peritonei according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of intracellular pH GO:0051453 9.32 CA2 TP53
2 DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediator GO:0006978 9.26 MUC1 TP53
3 O-glycan processing GO:0016266 9.26 MUC1 MUC2 MUC5AC MUC6
4 maintenance of gastrointestinal epithelium GO:0030277 9.16 MUC2 MUC6
5 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.02 KRAS MUC1 MUC2 MUC5AC MUC6

Sources for Pseudomyxoma Peritonei

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....